Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy

• Published in: The journal of clinical endocrinology and metabolism Vol. 77; no. 4; p. 1090
• Main Authors: Sisson, J C, Ackermann, R J, Meyer, M A, Wahl, R L
• Format: Journal Article
• Language: English
• Published: United States 01-10-1993
• Subjects: Carcinoma, Papillary - diagnostic imaging; Carcinoma, Papillary - drug therapy; Carcinoma, Papillary - metabolism; Carcinoma, Papillary - secondary; Deoxyglucose - analogs & derivatives; Deoxyglucose - pharmacokinetics; Fluorodeoxyglucose F18; Humans; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - secondary; Male; Middle Aged; Thyroglobulin - blood; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - pathology; Thyrotropin - blood; Thyroxine - blood; Thyroxine - therapeutic use; Tomography, Emission-Computed
• ISSN: 0021-972X
• DOI: 10.1210/jc.77.4.1090

A patient developed a pulmonary metastasis from papillary thyroid carcinoma. This tumor concentrated relatively little 131I, but sufficient 18F-fluoro-2-deoxy-D-glucose (FDG) to be quantified and imaged by positron emission tomography. The uptake of FDG was lower on positron emission tomographic images after T4 therapy and when the serum TSH concentration was reduced to the low normal range. It may be possible to use decreases in FDG uptake by thyroid cancers, which represent declines in metabolism by the tumors, to indicate the optimum doses of T4 treatment for patients with these neoplasms. In addition, the ratio of tumor to background radioactivity was higher for FDG than for the flow agent 201Tl, so that studies with FDG may be a useful scintigraphic method for locating thyroid cancers when radioiodine imaging is unsatisfactory.